In a new study, researchers from the University of California-Los Angeles studied tumor response and overall survival following the administration of a new treatment among patients with advanced melanoma. This agent, called pembrolizumab, is an antibody that blocks PD-1, a protein which prevents the body's immune system from attacking the cancer.
The researchers tested pembrolizumab on more than 650 patients in North America, Europe and Australia. They looked at tumor response before and after treatment and found that the lesions were smaller in about one third of patients. In patients who responded to the treatment, seventy-five percent maintained the response at one or two years.
Source: Thenewsmarket
GMT 17:15 2017 Thursday ,16 November
30 research papers for Shaikh Nasser AwardGMT 17:09 2017 Thursday ,16 November
Hormone shows promise for treating neurodegenerative conditionsGMT 20:44 2017 Tuesday ,07 November
Here's how UAE teachers can get a free trip to USGMT 00:37 2017 Monday ,30 October
Minister receives researcherGMT 00:34 2017 Monday ,30 October
Research, science, innovation to contribute challenges in EgyptGMT 08:08 2017 Monday ,03 July
MBRSG launches "Academy of International Business"GMT 11:49 2017 Wednesday ,21 June
TRA Innovation Camp's registrationGMT 21:22 2017 Wednesday ,24 May
Jordanian scientists to access researchMaintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2021 ©
Maintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2021 ©
Send your comments
Your comment as a visitor